Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents

Bibliography

• DREW J: Drug discovery: a historical perspective. Science (2000) 287:1960–1964.
   PubMed Web of Science ®Google Scholar
• OWA T, NAGASU T: Novel sulfonamide derivatives for the treatment of cancer. Exp. Opin. Ther: Patents (2000) 10:1725–1740.
   Web of Science ®Google Scholar
• •Excellent review of anticancer sulfonamides.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Titer: Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• ••Comprehensive review on the applicationof carbonic anhydrase inhibitors in therapy.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Exp. Opin. Ther: Patents(2002) 12:217–242.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors. Curr. Med. Chem. him Endoc. Metab. Agents (2001) 1:61–97.
   Google Scholar
• ••This paper presents the most completereview on the chemistry and enzyme inhibitory activity of primary sulfonamides and related compounds interacting with carbonic anhydrases.
   Google Scholar
• MARENTH: Relations between structure and biological activity of sulfonamides. Anna. Rev Pharmacol Toxicol (1976) 16:309–327.
   PubMedGoogle Scholar
• SUPURAN CT, CONROY CW, MAREN TH: Carbonic anhydrase inhibitors. Synthesis and inhibitory properties of 1,3,4-thiadiazole-2,5-bissulfonamide. Eur..1. Med. Chem. (1996) 31:843–846.
   Google Scholar
• BOYD AE: Sulfonylurea receptors, ion channels and fruit flies. Diabetes (1988) 37:847–850.
   PubMed Web of Science ®Google Scholar
• THORNBER CW: Isosterism and molecular modification in drug design. Chem. Soc. Rev (1979) 8:563–580.
   Web of Science ®Google Scholar
• OGDEN RC, FLEXNER CW (Eds): Protease Inhibitors M AIDS Therapy Marcel Dekker, New York, Basel (2001).
   Google Scholar
• ••An excellent book on protease inhibitors asanti-HIV agents.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A, MASTROLORENZO A: Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Exp. Opin. Ther. Patents (2001) 11:221–259.
   Web of Science ®Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. I Med. Chem. (2000) 43:3677–3687.
   Google Scholar
• ••The first report of hydroxarnates wih potent carbonic anhydrase inhibitory activity.
   Google Scholar
• WOUTERS J, MICHAUX C, DURANT F, DOGNE. JM, DELARGE J, MASEREEL B: Isosterism among analogues of torasemide: conformational, electronic and lipophilic properties. Ear: j Med. Chem. (2000) 35:923–929.
   PubMed Web of Science ®Google Scholar
• BUOLAMWINI JK: Novel anticancer drug discovery. Carr: Opin. Chem. Biol. (1999) 3:500–509.
   PubMed Web of Science ®Google Scholar
• LEHNERT M: Clinical multidrug resistance in cancer: a multifactorial problem. Eur: J. Cancer (1996) 6:912–920.
   Google Scholar
• LOO TW, CLARKE DM: Blockage of drug resistance M vitro by disulfiram, a drug used to treat alcoholism. Nail Cancer Inst. (2000) 92:898–902.
   PubMed Web of Science ®Google Scholar
• JONES DA, FITZPATRICK FA: Genomics and the discovery of new drug targets. Curt: Opin. Chem. Biol. (1999) 3:71–76.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, MILLER MD, HAZUDA DJ, EMINI EA: Potential new therapies for the treatment of HIV-1 infection. Ann. Rev Med. (2002) 53:541–555.
   PubMedGoogle Scholar
• ••Excellent review on novel types oftherapeutic approaches against the HIV infection.
   Google Scholar
• VELLA S, PALMISANO L: Antiretroviral therapy: state of the HAART. Antiviral Res. (2000) 45:1–7.
   PubMed Web of Science ®Google Scholar
• ••A very good review on HAART.
   Google Scholar
• JOLY V, YENY P: New trends in antiretroviral therapy of HIV infection. Eur. Int. Med. (2000) 11:301–308.
   PubMedGoogle Scholar
• SUPURAN CT, SCOZZAFAVA A: Matrix metalloproteinases (MMPs). In: Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Smith HJ, Simons C (Eds), Taylor & Francis, London and New York, (2002):35–61.
   Google Scholar
• •Updated review on MMP inhibitors.
   Google Scholar
• WOESSNER JF, NAGASE H: Matrix metalloproteinases and TIMPs. Oxford Univ. Press, Oxford (2000):1–223.
   Google Scholar
• MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. Med. Chem. (1997) 40:2525–2532
   Web of Science ®Google Scholar
• ••The first report of sulfonylated amino acidhydroxymates as MMP inhibitors.
   Google Scholar
• WHITTAKER M, FLOYD CD, BROWN P, GEARING AJH: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• ••A very good review on MMP inhibitors.
   Google Scholar
• HANESSIAN S, BOUZBOUZ S, BOUDON A, TUCKER GC, PEYROULAN D: Picking the Si, Sr and Sz pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg. Med. Chem. Lett. (1999) 9:1691–1696.
   Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Protease inhibitors. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating N-4-nitrobenzylsulfonyl glycine hydroxamate moieties. Med. Chem. (2000) 43:1858–1865
   Google Scholar
• CLARE BW, SCOZZAFAVA A, SUPURAN CT: Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type. I Med. Chem. (2001) 44:2253–2258.
   PubMedGoogle Scholar
• •A report of potent hydroxamate inhibitors of bacterial proteases.
   Google Scholar
• OHTA M, KONNO H, TANAKA T: Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. fpn. .1. Cancer Res. (2001) 92:688–695.
   PubMedGoogle Scholar
• PIKUL S, MCDOW DUNHAM K, ALMSTEAD NG et al.: Heterocycle-based MMP inhibitors with P2' substituents. Bioorg. Med. Chem. Lett. (2001) 11:1009–1013.
   PubMed Web of Science ®Google Scholar
• BAXTER AD, BHOGAL R, BIRD J et al:Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:1465–1468.
   PubMed Web of Science ®Google Scholar
• •A new type of structural variant of sulfonylated amino acid hydroxamates.
   Google Scholar
• BARTA TE, BECKER DP, BEDELL LJ et al: Selective, orally active MMP inhibitors with an aryl backbone. Bioorg. Med. Chem. Lett (2001) 11:2481–2483.
   PubMed Web of Science ®Google Scholar
• LEVIN JI, GUY, NELSON FC et al.: Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorg. Med. Chem. Lett (2001) 11:239–242.
   PubMedGoogle Scholar
• SCHRODER J, HENKE A, WENZEL H et al.: Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. Med. Chem. (2001) 44:3231–3243.
   Google Scholar
• DANKWARDT SM, MARTIN RL, CHAN CS et al.: Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues. Bioorg. Med. Chem. Lett (2001) 11:2085–2088.
   PubMedGoogle Scholar
• DANKWARDT SM, ABBOT SC, BROKA CA et al: Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase. Part 2. Solid-phase optimization of side chains. Bioorg. Med. Chem. Lett. (2002) 12:1233–1235.
   PubMedGoogle Scholar
• BLACK RA: Tumor necrosis factor-a converting enzyme. Int. j Biochem. Biol. (2002) 34:1–5.
   PubMed Web of Science ®Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper for the research of TACEinhibitors.
   Google Scholar
• MOSS ML, WHITE JM, LAMBERT WH, ANDREWS RC: TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today(2001) 6:417–426.
   PubMed Web of Science ®Google Scholar
• GOMIS-RUTH X, MEYER E, KRESS LF, POLITI V: Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor-a convertase inhibitors. Protein Sci. (1998) 7:283–292.
   Google Scholar
• BARLAAM B, BIRD T, VAN DER BREMPT LC, CAMPBELL D, FOSTER SJ, MAKIEWICZ R: New a-substituted succinate-based TNF-a convertase inhibitors. Med. Chem. (1999) 42:4890–4908.
   Google Scholar
• CHEN JM, JIN G, SUNG A, LEVIN JI: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: structure-based design of novel acetylenic P1' groups. Bioorg. Med. Chem. Lett. (2002) 12:1195–1198.
   Google Scholar
• LEVIN JI, CHEN JM, DU MT et al.: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic PF group. Bioorg. Med. Chem. Lett. (2002) 12:1199–1202.
   Google Scholar
• LETAVIC MA, AXT MZ, BARBERIA JT: Synthesis and biological activity of selective pipecolic acid-based TNF-a converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1387–1390.
   PubMed Web of Science ®Google Scholar
• EDWARDS PD: Human neutrophil elastase inhibitors. In: Proteinase and Peptidase Inhibition - Recent Potential Targets for Drug Development. Smith HJ, Simons C (Eds), Taylor & Francis, London and New York (2002):154–177.
   Google Scholar
• AN-ZHI W, MAYR I, BODE W: The refined 2.3 A crystal structure of human leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor. FEBS Lett. (1988) 234:367–373.
   Google Scholar
• DE NANTEUIL G, PORTEVIN B, BENOIST A: Disease-modifying anti-ostheoarthritic drugs: current therapies and new prospects around protease inhibition. Farmaco (2001) 56:107–112.
   PubMedGoogle Scholar
• TOMIZAWA N, OHWADA S, OHYA T et al.: The effects of a neutrophil elastase inhibitor (ON0-5046 Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs. I Heart Lung Transplant. (1999) 18: 637–645.
   PubMedGoogle Scholar
• KIRSCEHNHEUTER GP, OLEKSYSZYN J, LYLE W et al.: Synthesis and characterization of human neutrophil elastase inhibitors derived from aromatic esters of phenylalkanoic acids. Agents Act. (1993) 42:71–82.
   PubMedGoogle Scholar
• GROUTAS WC, HE S, KUANG R, RUAN S, TU J, CHAN HK: Inhibition of serine proteases by functionalised sulfonamides coupled to the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold. Bioorg. Med. Chem. (2001) 9:1543–1548.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, WOLFF SM: The role of interleukin-1 in disease. N Engl. Med (1993) 328:106–113.
   PubMed Web of Science ®Google Scholar
• WILSON KP, BLACK JF, THOMSON JA, et al.: Structure and mechanism of interleukin-1 13 converting enzyme. Nature (1994) 370:270–275.
   Google Scholar
• WALKER NPC, TALANIAN RV, BRADY D et al.: Crystal structure of the cysteine protease interleukin-1 I3-converting enzyme: a (p20/ p10)2 homodimer. Cell (1994) 78:343–352.
   PubMedGoogle Scholar
• SHAHRIPOUR AB, PLUMMER MS, LUNNEY EA et al.: Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide. Bioorg. Med. Chem. Lett. (2001) 11:2779–2782.
   PubMedGoogle Scholar
• LEE D, LONG SA, MURRAY JH, et al: Potent and selective nonpeptide inhibitors of caspases 3 and 7. Med. Chem. (2001) 44:2015–2026.
   Google Scholar
• RUKAMP B, POWERS JC: Cathepsins. In: Proteinase and Peptidase Inhibition - Recent Potential Targets for Drug Development. Smith HI, Simons C (Eds), Taylor & Francis, London and New York (2002):84–126.
   Google Scholar
• FALGUEYERET JP, OBALLA RIVI, OKAMOTO O et al.: Novel, non-peptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. Med. Chem. (2001) 44:94–104.
   Google Scholar
• DE CLERCQ E: Antiviral drugs: current state of the art. Clin. Vim]. (2001) 22:73–89.
   PubMed Web of Science ®Google Scholar
• RICHMAN DR: HIV chemotherapy. Nature (2001) 410:995–1001.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: New developments in anti-HIV chemotherapy. Curc Med. Chem. (2001) 8:1543–1572.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on antivirals.
   Google Scholar
• DE CLERCQ E: Molecular targets for antiviral agents. Pharmacol. Exp. Ther: (2001) 297:1–10.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Strategies in the design of antiviral drugs. Nat. Drug Discov (2002) 1:13–25.
   PubMed Web of Science ®Google Scholar
• ••A very interesting and well written reviewon antivirals.
   Google Scholar
• ERICKSON JW: HIV-1 protease as a target for AIDS therapy. In: Protease Inhibitors in AIDS Therapy Ogden RC, Flexner CW (Eds), Marcel Dekker, New York (2001):1–25.
   Google Scholar
• TUNG RD, LIVINGSTON DJ, RAO BG et al.: Design and synthesis of amprenavir, a novel HIV protease inhibitor. In Protease Inhibitors in AIDS Therapy Ogden RC, Flexner CW (Eds), Marcel Dekker, New York (2001):101–118.
   Google Scholar
• CHRUSCIEL RA, THAISRIVONGS S, NICHOLAS JA: HIV protease inhibitors in early development. In: Protease Inhibitors M AIDS Therapy Ogden RC, Flexner CW (Eds), Marcel Dekker, New York (2001):119–137.
   Google Scholar
• WLODAWER A, GUSTCHINA A: Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta. (2000) 1477:16–34.
   PubMed Web of Science ®Google Scholar
• SCHECHTER I, BERGER A: On the size of the active site in proteases in papain. Biochem. Biophys. Res. Commun. (1967) 27:157–162.
   PubMed Web of Science ®Google Scholar
• GATELL JM: From amprenavir to GW433908. J. HIV Mei: (2001) 6:95–99.
   Google Scholar
• GHOSH AK, SHIN D, SWANSON L et al: Structure-based design of non-peptide HIV protease inhibitor. Farmaco (2001) 56:29–32.
   PubMedGoogle Scholar
• RUSCONI S, LA SETA CATAMANCIO S: HIV-1 protease inhibitors in development. Expert Opin. Investig. Drugs(2002) 11:387–395.
   PubMedGoogle Scholar
• ••A very good review on new HIV PIs inclinical development.
   Google Scholar
• DE MEYER S, AZIJN H, VAN GINDEREN M, DE BAERE I, PAUWELS R, DE BETHUNE MP: In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed protease inhibitors. Antiviral Therapy (2002) 7:S5.
   Google Scholar
• ••Presents seminal results demonstratingreduced resistance of HIV against a new PI, TMC 114.
   Google Scholar
• TURNER SR, STROHBACH JW, TOMMASI RA et al.: Tipranavir (PNU-140690): a potent, orally bioavailable non-peptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Med. Chem. (1998) 41:3467–3476.
   Google Scholar
• SKULNICK HI, JOHNSON PD, ARISTOFF PA et al.: Structure-based design of non-peptidic HIV protease inhibitor: the sulfonamide-substituted cyclooctylpyranones.j. Med. Chem. (1997) 40:1149–1164.
   PubMed Web of Science ®Google Scholar
• LEE YS, LEE JY, KIM SN, LEE CK, PARK H: 6 -Hydroxy- 1, 3 -dioxin-4- ones as non-peptidic HIV protease inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:2625–2627.
   PubMedGoogle Scholar
• DORSEY BD, VACCA JP Discovery and early development of indinavir. In: Protease Inhibitors M AIDS Therapy Ogden RC, Flexner CW (Eds), Marcel Dekker, New York (2001):65–83.
   Google Scholar
• HULTEN J, BONHAM NM, NILLROTH U et al.: Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies and computational predictions of binding affinities. Med. Chem. (1997) 40:885–897.
   Google Scholar
• BACKBRO K, LOWGREN S, OSTERLUND K et al.: Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Med. Chem. (1997) 40:898–902.
   Google Scholar
• HULTEN J, ANDERSSON HO, SCHAAL W et al.: Inhibitors of the C2-symmetric HIV-1 protease: Non-symmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/ P2' side chains. Med. Chem. (1999) 42:4054–4061.
   Google Scholar
• JAR VEST RL, DABROWSKI CE: Herpesvirus and cytomegalovirus proteinase. In ProteMase and Peptidase Inhibition - Recent Potential Targets for Drug Development. Smith HJ, Simons C (Eds), Taylor & Francis, London and New York (2002):264–281.
   Google Scholar
• RAWLINSON WD: Diagnosis of human cytomegalovirus infection and disease. Pathology (1999) 31:109–115.
   PubMed Web of Science ®Google Scholar
• ENSOLI B, STURZL M, MONINI P: Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv. Cancer Res. (2001) 81:125–159.
   PubMedGoogle Scholar
• BORTHWICK AD, CRAME AJ, ERTL PF et al: Design and synthesis of pyrrolidine-5,5- trans-lactams (5-oxohexahydropyrrolo [3,2-blpyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. potency and chirality. j Med. Chem. (2002) 45:1–18.
   PubMedGoogle Scholar
• SHIEH HS, KURUMBAIL RG, STEVENS AM et al.: Three dimensional structure of human cytomegalovirus protease. Nature (1996) 383:279–282.
   PubMed Web of Science ®Google Scholar